According to BMO Capital Markets, Medicare coverage of Lilly’s Zepbound opens the door to using secondary indications to ...

Being laid off is bad enough. When companies mishandle the layoff process, it can make the situation even worse. Four ...

J.P. Morgan releases its annual look-ahead days before the entire biopharma industry descends on San Francisco for the annual ...

By mid-2025, the biotech will split into two entities: a new, as-yet-unnamed innovative medicines specialist and a cell ...

Backed by ARCH Venture Partners, F-Prime Capital and Mubadala Capital, the new company will develop a pipeline of ...

Licensing deals have risen in prominence in a restrained market environment. Is it desperation, or an important part of the ...

Look for renewed investment driven by lower interest rates in the new year, and a continued focus on late-stage assets, ...

M&A didn’t return as hoped for in 2024. The biopharma industry is heading into the J.P. Morgan Healthcare Conference next ...

In a rare move, the FDA recommended a minimum of 5% weight-loss for drug developers seeking to establish the efficacy of ...

A post-marketing review by the FDA detected an increased risk of the autoimmune condition in patients inoculated with GSK’s ...

The investment continues a Novo dealmaking spree to cement its leadership status in the cardiometabolic space, with ...

Maze’s IPO comes on the heels of its oversubscribed Series D funding round, which infused the biotech with $115 million in ...